Bioisosteric Replacement of Arylamide-Linked Spine Residues with N -Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38α MAP Kinase Inhibitors Documento